
Outset Medical (OM) Stock Forecast & Price Target
Outset Medical (OM) Analyst Ratings
Bulls say
Outset Medical is expected to maintain strong sales growth with revenues projected to increase 5-9% year over year in 2026, driven by a growing deal pipeline and the launch of their next-gen Tablo system. The company also has a good track record of meeting or exceeding their sales guidance, with a strong recurring revenue base from consumables and service contracts. With a focus on improving margins and lengthening their cash runway, and a solid clinical and technical advantage with their Tablo system, Outset Medical is well-positioned for success in the dialysis market.
Bears say
Outset Medical is a Buy, as its technology has been accepted by the largest providers and offers simpler and more convenient dialysis treatment, but the company is facing near-term commercial headwinds and is working on improving its gross margin and reducing operating spend. With a large market opportunity ahead, the company has potential for long-term growth, but execution hurdles may hinder near-term performance.
This aggregate rating is based on analysts' research of Outset Medical and is not a guaranteed prediction by Public.com or investment advice.
Outset Medical (OM) Analyst Forecast & Price Prediction
Start investing in Outset Medical (OM)
Order type
Buy in
Order amount
Est. shares
0 shares